2018 Utah Communicable Disease Rule Changes

Electronic Reporters

R386-702, The Utah Communicable Disease Rule, has been updated. The rule can be found at the Division of Administrative Rules website: https://rules.utah.gov/publicat/code/r386/r386-702.htm. Additional information is also available at http://health.utah.gov/epi/reporting. Following is a summary of important changes for electronic reporters.

New additions to reportable conditions

- Chagas Disease
- Middle East Respiratory Syndrome (MERS)
- Pseudomonas aeruginosa (resistant to a carbapenem, or with demonstrated carbapenemase production)
- MRSA (Methicillin-resistant Staphylococcus aureus), MSSA (Methicillin-susceptible Staphylococcus aureus)
- Candida auris and Candida haemulonii
- Anthrax-like illness, caused by Bacillus cereus strains that express anthrax toxin genes

Selected antimicrobial susceptibility test results are reportable

The current revision mandated antimicrobial susceptibility testing when performed selected organisms. Full panel antibiotic susceptibility test results, including minimum inhibitory concentration results and results suppressed to the ordering clinician, are reportable when performed on the following organisms:

- Candida auris/Candida haemulonii from any body site
- Mycobacterium tuberculosis
- Neisseria gonorrhoeae
- Salmonella species
- Shigella species
- Streptococcus pneumoniae
- Organisms resistant to a carbapenem, or with demonstrated carbapenemase, in:
  - Acinetobacter species
  - Enterobacter species
  - Escherichia coli
  - Klebsiella species
  - Pseudomonas aeruginosa
- Organisms resistant to vancomycin in:
  - Staphylococcus aureus (VRSA)

Additionally, all individual carbapenemase test results (positive, negative, equivocal, indeterminate), including the method used, are reportable when performed on organisms resistant to a carbapenem, or with demonstrated carbapenemase, in:

- Acinetobacter species
- Enterobacter species
- Escherichia coli
- Klebsiella species

Finally, human immunodeficiency virus (HIV) antiviral susceptibility test results; including nucleotide sequencing, genotyping, or phenotypic analysis; are now reportable.

Removed reportable conditions

- Vancomycin-intermediate Staphylococcus aureus (VISA)

Questions

Contact the DCP Informatics Program at (801) 538-6191 or elr@utah.gov.